Vimarsana
Biggest News Aggregation in the World

Page 29 - Ir Team News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ir Team. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ir Team Today - Breaking & Trending Today

Junshi Biosciences and Coherus Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody - Vimarsana News

Junshi Biosciences and Coherus Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody

Junshi Biosciences and Coherus plan to evaluate the toripalimab + JS006 combination in clinical trials in multiple tumor typesCombinations of PD-1 + TIGIT inhibitors have potential to expand... | January 10, 2022

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences and Coherus Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody - Vimarsana News

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences and Coherus Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody

Investegate announcements from Junshi Biosciences, Junshi Biosciences and Coherus Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody

Junshi Biosciences and DotBio Announce Collaboration to Develop Next-Generation Antibody Therapy with DotBody Module - Vimarsana News

Junshi Biosciences and DotBio Announce Collaboration to Develop Next-Generation Antibody Therapy with DotBody Module

SHANGHAI, China and SINGAPORE, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biociences Co., Ltd ("Junshi Biosciences", HKEX: 1877, SSE: 688180), a leading innovation-driven biopharmaceutical company

Kintor Pharma Provides Update on One of its Three Multi-Regional Phase 3 Trials of Proxalutamide for COVID-19 - Vimarsana News

Kintor Pharma Provides Update on One of its Three Multi-Regional Phase 3 Trials of Proxalutamide for COVID-19

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Kintor Pharma Provides Update on One of its Three Multi-Regional Phase 3 Trials of Proxalutamide for COVID-19 - Vimarsana News

Kintor Pharma Provides Update on One of its Three Multi-Regional Phase 3 Trials of Proxalutamide for COVID-19

SUZHOU, China, Dec. 27, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today provided an update on its multi-regional study of proxalutamide for the treatment of COVID-19 infection (NCT04870606). Statistical criteria were not met at an interim analysis of the phase III outpatient study, designed for...